Literature DB >> 15832293

Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA.

Birgit Scheel1, Regina Teufel, Jochen Probst, Jean-Philippe Carralot, Jens Geginat, Markus Radsak, David Jarrossay, Hermann Wagner, Günther Jung, Hans-Georg Rammensee, Ingmar Hoerr, Steve Pascolo.   

Abstract

We reported that RNA condensed on protamine is protected from RNase-mediated degradation and can be used for vaccination. Here, we show that such complexes are also danger signals that activate mouse cells through a MyD88-dependent pathway. Moreover, mRNA-protamine complexes stimulate human blood cells. They strongly activate DC and monocytes, leading to TNF-alpha and IFN-alpha secretion. In addition, protamine-RNA complexes directly activate B cells, NK cells and granulocytes. The detailed analysis of the activated cell types, the study of the cytokines released from PBMC cultured with protamine-RNA complexes and recently published results suggest that TLR-7 and TLR-8 may be involved in the recognition of protamine-stabilized RNA. Our data indicate that protamine-stabilized RNA, which may be similar to RNA condensed in the nucleocapsids of RNA viruses, is a strong danger signal. Thus, similarly to plasmid DNA, protamine-RNA combines antigen production and non-specific immunostimulation. The studies presented here explain the capacity of protamine-RNA to act as a vaccine, and pave the way towards the development of safe and efficient mRNA-based immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15832293     DOI: 10.1002/eji.200425656

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  56 in total

1.  Interferon-α and interleukin-12 are induced, respectively, by double-stranded DNA and single-stranded RNA in human myeloid dendritic cells.

Authors:  Yuichi Katashiba; Rie Miyamoto; Akira Hyo; Keiko Shimamoto; Naoko Murakami; Makoto Ogata; Ryuichi Amakawa; Muneo Inaba; Shosaku Nomura; Shirou Fukuhara; Tomoki Ito
Journal:  Immunology       Date:  2010-09-28       Impact factor: 7.397

2.  Accessory-cell-mediated activation of porcine NK cells by toll-like receptor 7 (TLR7) and TLR8 agonists.

Authors:  Felix N Toka; Charles K Nfon; Harry Dawson; William T Golde
Journal:  Clin Vaccine Immunol       Date:  2009-04-15

3.  Expression of sperm-specific protamines impairs bacterial and eukaryotic cell proliferation.

Authors:  Katharina Günther; Agnieszka Paradowska-Dogan; Birte Bärmann; Harald Klein; Christoph von Eichel-Streiber; Ricardo Hartley; Wolfgang Weidner; Rüdiger Behr; Klaus Steger
Journal:  Histochem Cell Biol       Date:  2015-02-04       Impact factor: 4.304

Review 4.  Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery.

Authors:  Piotr S Kowalski; Arnab Rudra; Lei Miao; Daniel G Anderson
Journal:  Mol Ther       Date:  2019-02-19       Impact factor: 11.454

Review 5.  Developing mRNA-vaccine technologies.

Authors:  Thomas Schlake; Andreas Thess; Mariola Fotin-Mleczek; Karl-Josef Kallen
Journal:  RNA Biol       Date:  2012-10-12       Impact factor: 4.652

6.  A cationic nanoemulsion for the delivery of next-generation RNA vaccines.

Authors:  Luis A Brito; Michelle Chan; Christine A Shaw; Armin Hekele; Thomas Carsillo; Mary Schaefer; Jacob Archer; Anja Seubert; Gillis R Otten; Clayton W Beard; Antu K Dey; Anders Lilja; Nicholas M Valiante; Peter W Mason; Christian W Mandl; Susan W Barnett; Philip R Dormitzer; Jeffrey B Ulmer; Manmohan Singh; Derek T O'Hagan; Andrew J Geall
Journal:  Mol Ther       Date:  2014-07-16       Impact factor: 11.454

Review 7.  Nanoscale platforms for messenger RNA delivery.

Authors:  Bin Li; Xinfu Zhang; Yizhou Dong
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-05-04

Review 8.  mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer.

Authors:  Steffen Rausch; Christian Schwentner; Arnulf Stenzl; Jens Bedke
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  Biomaterials for mRNA delivery.

Authors:  Mohammad Ariful Islam; Emma K G Reesor; Yingjie Xu; Harshal R Zope; Bruce R Zetter; Jinjun Shi
Journal:  Biomater Sci       Date:  2015-08-17       Impact factor: 6.843

Review 10.  RNA vaccines in cancer treatment.

Authors:  Anita Bringmann; Stefanie Andrea Erika Held; Annkristin Heine; Peter Brossart
Journal:  J Biomed Biotechnol       Date:  2010-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.